Loading cancer entity…
Loading cancer entity…
Clinical trials
4,036 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (701)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06788756 | L-Annamycin for Injection in Combination With Cytarabine Injection as Second Line Therapy for Remission Induction in Adult Subjects With Refractory/Relapsed AML | recruiting | Phase 2 / Phase 3 | 312 | Moleculin Biotech, Inc.INDUSTRY | 9 | Aug 5, 2026 | clinicaltrials |
| NCT07740603 | Study of CD38 and CD56 in Chronic Myeloid Leukemia | not yet recruiting | — | 200 | Sohag UniversityOTHER | 0 | Aug 5, 2026 | clinicaltrials |
| NCT07748455 | HMA-Venetoclax Induction in Newly Diagnosed AML(VENTURE-AML) | not yet recruiting | Phase 2 | 60 | Pakistan Blood and Marrow Transplant (PBMT) GroupOTHER | 1 | Aug 5, 2026 | clinicaltrials |
| NCT06177067 | Study of Revumenib, Azacitidine, and Venetoclax in Pediatric and Young Adult Patients With Refractory or Relapsed Acute Myeloid Leukemia | recruiting | Phase 1 | 24 | St. Jude Children's Research HospitalOTHER | 1 | Aug 3, 2026 | clinicaltrials |
| NCT07743112 | A Phase 2 Study of MAX-40279 Combined With Venetoclax and Azacitidine in Unfit Newly Diagnosed Acute Myeloid Leukemia | recruiting | Phase 2 | 43 | Maxinovel Pty., Ltd.INDUSTRY | 1 | Aug 3, 2026 | clinicaltrials |
| NCT06985147 | A Phase 2, Open-Label Study of DISC-3405 in Participants With Polycythemia Vera (PV) | active not recruiting | Phase 2 | 60 | Disc Medicine, IncINDUSTRY | 1 | Jul 31, 2026 | clinicaltrials |
| NCT07679334 | Phase I Trial of Pacritinib in Combination With Venetoclax and Azacitidine for the Treatment of Accelerated and Blast Phase Myeloproliferative Neoplasms | not yet recruiting | Phase 1 | 20 | Roswell Park Cancer InstituteOTHER | 1 | Jul 31, 2026 | clinicaltrials |
| NCT02727803 | Personalized NK Cell Therapy in CBT | recruiting | Phase 2 | 100 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 30, 2026 | clinicaltrials |
| NCT04975919 | Venetoclax in Combination With Decitabine and Cedazuridine for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia | active not recruiting | Phase 2 | 20 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 30, 2026 | clinicaltrials |
| NCT05457556 | Mismatched Related Donor Versus Matched Unrelated Donor Stem Cell Transplantation for Children, Adolescents, and Young Adults With Acute Leukemia or Myelodysplastic Syndrome | active not recruiting | Phase 3 | 66 | Children's Oncology GroupNETWORK | 3 | Jul 30, 2026 | clinicaltrials |
| NCT07548710 | Study of SA+X in the Treatment of Newly Diagnosed AML | recruiting | Phase 2 | 205 | Ruijin HospitalOTHER | 1 | Jul 30, 2026 | clinicaltrials |
| NCT07737769 | Arsenic Trioxide to Prevent Relapse in Patients Undergoing Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia or Myelodysplastic Syndrome | not yet recruiting | Phase 1 | 20 | University of Michigan Rogel Cancer CenterOTHER | 1 | Jul 30, 2026 | clinicaltrials |
| NCT06034470 | Combination Chemotherapy (FLAG-Ida) With Pivekimab Sunirine (PVEK) for the Treatment of Newly Diagnosed Adverse Risk Acute Myeloid Leukemia and Other High-Grade Myeloid Neoplasms | active not recruiting | Phase 1 | 30 | Fred Hutchinson Cancer CenterOTHER | 1 | Jul 29, 2026 | clinicaltrials |
| NCT07734272 | Standardized Documentation and Assessments for Polycythemia Vera: A Quality Improvement Initiative(STANDARDIZE-PV) | not yet recruiting | N/A | 32 | Massachusetts General HospitalOTHER | 0 | Jul 29, 2026 | clinicaltrials |
| NCT07735117 | Mitoxantrone Hydrochloride Liposome, Cytarabine, G-CSF Plus Venetoclax vs. Azacitidine Plus Venetoclax for MDS-IB2 and Secondary/Elderly AML | not yet recruiting | Phase 3 | 168 | Ruijin HospitalOTHER | 0 | Jul 29, 2026 | clinicaltrials |
| NCT07735208 | Geriatric Assessment-Guided Treatment Selection in Older Adults With Acute Myeloid Leukemia(ALIGN-AML) | not yet recruiting | Phase 2 | 120 | University of RochesterOTHER | 1 | Jul 29, 2026 | clinicaltrials |
| NCT02506933 | Multi-antigen CMV-MVA Triplex Vaccine in Reducing CMV Complications in Patients Previously Infected With CMV and Undergoing Donor Hematopoietic Cell Transplant | active not recruiting | Phase 2 | 102 | City of Hope Medical CenterOTHER | 1 | Jul 28, 2026 | clinicaltrials |
| NCT04093570 | A Study for Participants Who Participated in Prior Clinical Studies of ASTX727 (Standard Dose) | enrolling by invitation | Phase 2 | 332 | Taiho Oncology, Inc.INDUSTRY | 13 | Jul 28, 2026 | clinicaltrials |
| NCT05362773 | A Study of MGD024 in Patients With Relapsed or Refractory Hematologic Malignancies | active not recruiting | Phase 1 | 130 | MacroGenicsINDUSTRY | 1 | Jul 28, 2026 | clinicaltrials |
| NCT07020533 | A Vaccine (CMV-MVA Triplex Vaccine) for the Enhancement of CMV-Specific Immunity and the Prevention of CMV Viremia in Patients Undergoing Haploidentical Hematopoietic Stem Cell Transplant | recruiting | Phase 1 | 46 | City of Hope Medical CenterOTHER | 1 | Jul 28, 2026 | clinicaltrials |
| NCT07717164 | PRAISE-IR Versus CIBMTR Controls | not yet recruiting | — | 51 | Miltenyi Biomedicine GmbHINDUSTRY | 1 | Jul 28, 2026 | clinicaltrials |
| NCT05189639 | A Study To Learn About the Safety Medicine (Called Mylotarg) In People With Acute Myeloid Leukemia | recruiting | — | 165 | PfizerINDUSTRY | 1 | Jul 24, 2026 | clinicaltrials |
| NCT07392970 | Motixafortide for MRD Sensitization in AML | recruiting | Phase 2 | 10 | Washington University School of MedicineOTHER | 1 | Jul 24, 2026 | clinicaltrials |
| NCT03934372 | Safety and Efficacy of Ponatinib for Treatment of Pediatric Recurrent or Refractory Leukemias, Lymphomas or Solid Tumors | recruiting | Phase 1 / Phase 2 | 70 | Incyte Biosciences International SàrlINDUSTRY | 7 | Jul 23, 2026 | clinicaltrials |
| NCT06945042 | ONC-LEUK-2406: The Impact of Systematic Financial Navigation in Acute Myeloid Leukemia | recruiting | N/A | 120 | Wake Forest University Health SciencesOTHER | 1 | Jul 23, 2026 | clinicaltrials |
| NCT07722767 | A Phase 1b Study of CLN-049 in Combination With Azacitidine and Venetoclax in AML Patients | not yet recruiting | Phase 1 | 90 | Cullinan Therapeutics Inc.INDUSTRY | 1 | Jul 23, 2026 | clinicaltrials |
| NCT04285086 | Ropeginterferon Alfa-2b (P1101) vs. Anagrelide in Essential Thrombocythemia Patients With Hydroxyurea Resistance or Intolerance(SURPASS ET) | active not recruiting | Phase 3 | 174 | PharmaEssentiaINDUSTRY | 8 | Jul 22, 2026 | clinicaltrials |
| NCT04603001 | Study of Oral LY3410738 in Patients With Advanced Hematologic Malignancies With IDH1 or IDH2 Mutations | active not recruiting | Phase 1 | 260 | Eli Lilly and CompanyINDUSTRY | 12 | Jul 22, 2026 | clinicaltrials |
| NCT05143840 | Asciminib as Initial Therapy for Patients With Chronic Myeloid Leukemia in Chronic Phase(ALERTCML) | active not recruiting | Phase 2 | 100 | University of Alabama at BirminghamOTHER | 1 | Jul 22, 2026 | clinicaltrials |
| NCT06013423 | Cord Blood Transplant, Cyclophosphamide, Fludarabine, and Total-Body Irradiation in Treating Patients With High-Risk Hematologic Diseases | recruiting | Phase 2 | 54 | Fred Hutchinson Cancer CenterOTHER | 1 | Jul 22, 2026 | clinicaltrials |
| NCT07008638 | Phase I/II Clinical Trial of Proteasome Inhibitor in Combination With CPX-351 for the Treatment of Newly-Diagnosed TP53-mutated Acute Myeloid Leukemia (AML) | recruiting | Phase 1 / Phase 2 | 32 | Masonic Cancer Center, University of MinnesotaOTHER | 1 | Jul 22, 2026 | clinicaltrials |
| NCT07441694 | Study of INCA036978 in Participants With Myeloproliferative Neoplasms | recruiting | Phase 1 | 218 | Incyte CorporationINDUSTRY | 11 | Jul 22, 2026 | clinicaltrials |
| NCT07719348 | A Study to Evaluate S241656 Alone or in Combination in Participants With Selected Myeloid Malignancies | not yet recruiting | Phase 1 / Phase 2 | 64 | ServierINDUSTRY | 0 | Jul 22, 2026 | clinicaltrials |
| NCT03739502 | A Randomized Phase II Study of Hyperbaric Oxygen in Improving Engraftment in Umbilical Cord Blood Stem Cell Transplant(HBO-UBC) | active not recruiting | Phase 2 | 64 | University of RochesterOTHER | 1 | Jul 20, 2026 | clinicaltrials |
| NCT07155226 | Study of AZD3632 Monotherapy or in Combination With Anticancer Agents in Participants With Advanced Haematologic Malignancies With KMT2Ar, NPM1m, or Other Genotypes Associated With HOX Overexpression(MOMENTUM) | recruiting | Phase 1 / Phase 2 | 84 | AstraZenecaINDUSTRY | 9 | Jul 20, 2026 | clinicaltrials |
| NCT07250646 | A Study of Rebecsinib for Patients With Relapsed/Refractory Secondary Acute Myeloid Leukemia or High Risk Myelofibrosis | recruiting | Phase 1 | 28 | Aspera Biomedicines, Inc.INDUSTRY | 1 | Jul 20, 2026 | clinicaltrials |
| NCT07712848 | DEC3-VEN vs. Venetoclax-Based vs. DA Regimens in Newly Diagnosed AML | recruiting | Phase 3 | 291 | The Second Affiliated Hospital of Kunming Medical UniversityOTHER | 1 | Jul 20, 2026 | clinicaltrials |
| NCT02416388 | Study to Improve OS in 18 to 60 Year-old Patients, Comparing Daunorubicin Versus High Dose Idarubicin Induction Regimens, High Dose Versus Intermediate Dose Cytarabine Consolidation Regimens, and Standard Versus MMF Prophylaxis of GvHD in Allografted Patients in First CR(BIG-1) | recruiting | Phase 2 / Phase 3 | 3,100 | University Hospital, AngersOTHER_GOV | 1 | Jul 17, 2026 | clinicaltrials |
| NCT05429632 | Mocravimod as Adjunctive and Maintenance Treatment in AML Patients Undergoing Allo-HCT(MO-TRANS) | recruiting | Phase 3 | 366 | Priothera SASINDUSTRY | 14 | Jul 17, 2026 | clinicaltrials |
| NCT07392242 | A Study of the Combination of Ivosidenib, Azacitidine, and Venetoclax Followed by Ivosidenib Alone in People With Acute Myeloid Leukemia | recruiting | Phase 2 | 45 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jul 17, 2026 | clinicaltrials |
| NCT00923442 | Biology Studies of Hematologic Cancers | enrolling by invitation | — | 550 | National Cancer Institute (NCI)NIH | 1 | Jul 16, 2026 | clinicaltrials |
| NCT03817398 | Stopping Tyrosine Kinase Inhibitors in Affecting Treatment-Free Remission in Patients With Chronic Phase Chronic Myeloid Leukemia | active not recruiting | Phase 2 | 110 | Children's Oncology GroupNETWORK | 4 | Jul 16, 2026 | clinicaltrials |
| NCT03862157 | Azacitidine, Venetoclax, and Pevonedistat in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia | active not recruiting | Phase 1 / Phase 2 | 40 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 16, 2026 | clinicaltrials |
| NCT04062266 | AZA + Venetoclax as Maintenance Therapy in Patients With AML in Remission | active not recruiting | Phase 2 | 50 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 16, 2026 | clinicaltrials |
| NCT04231851 | CPX-351 and Glasdegib for Newly Diagnosed Acute Myelogenous Leukemia With MDS Related Changes or Therapy-related Acute Myeloid Leukemia | active not recruiting | Phase 2 | 30 | University of California, IrvineOTHER | 1 | Jul 16, 2026 | clinicaltrials |
| NCT04717414 | An Efficacy and Safety Study of Luspatercept (ACE-536) Versus Placebo in Subjects With Myeloproliferative Neoplasm-Associated Myelofibrosis on Concomitant JAK2 Inhibitor Therapy and Who Require Red Blood Cell Transfusions(INDEPENDENCE) | active not recruiting | Phase 3 | 313 | CelgeneINDUSTRY | 26 | Jul 16, 2026 | clinicaltrials |
| NCT05010772 | Decitabine Alone or in Combination With Venetoclax, Gilteritinib, Enasidenib, or Ivosidenib as Maintenance Therapy for the Treatment of Acute Myeloid Leukemia in Remission | recruiting | Phase 1 | 125 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 16, 2026 | clinicaltrials |
Data updated 23 days agoSource updated Aug 5, 2026source: clinicaltrials